Olivier Hartmann

Olivier Hartmann

Auto-generated profile, based on publicly available information

Olivier Hartmann

Pediatrics Department, Institut Gustave Roussy, Villejuif, France

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2003 in Cancer
Verified
Journal Article
Open access
PDF file
CBCeline Icher‐De Bouyn
Celine Icher‐De Bouyn
JLJerome Leclere
Jerome Leclere
GRGraziella Raimondo
Graziella Raimondo
HPHubert Ducou le Pointe
Hubert Ducou le Pointe
DCDominique Couanet
Dominique Couanet
OHOlivier Hartmann
Olivier Hartmann
BACKGROUND: The detection of hepatic nodules, particularly in patients treated for a previous malignancy, raises a diagnostic dilemma. Focal nodular hyperplasia (FNH) of the liver is an uncommon, benign tumor in children and must be differentiated from malignant hepatic lesions. The etiology of FNH is obscure, and its pathogenesis is poorly understood. FNH may be a reaction to localized vascular abnormalities and circulatory disturbances. The goal of the current study was to identify risk factors for the occurrence of FNH in children who had received prior treatment for a malignant tumor.METHODS: The current retrospective study examined 14 cases of FNH in pediatric patients who previously had been treated for a malignancy. Diagnosis was based on clinical and radiologic findings and was proven histologically in four cases.RESULTS: FNH lesions were discovered by chance during routine examination in 78% of patients. The incidence of FNH was particularly high in the current series (0.45%) compared with the incidence in the general pediatric population. High doses of alkylating agents (e.g., busulfan or melphalan), venoocclusive disease, and liver radiotherapy may be responsible for injury to the vascular endothelium and subsequent localized circulatory disturbances. FNH is characterized by the absence of complications after its detection; therefore, only close follow‐up is recommended.CONCLUSIONS: FNH appears to be a late complication of an iatrogenic vascular disease in children with a history of malignancy. Cancer 2003;97:3107–13. © 2003 American Cancer Society.DOI 10.1002/cncr.11452

15 November 1998
Verified
Journal Article
Closed access
LBL Brugières
L Brugières
MDM C Deley
M C Deley
HPH Pacquement
H Pacquement
ZMZ Meguerian-Bedoyan
Z Meguerian-Bedoyan
MTM J Terrier-Lacombe
M J Terrier-Lacombe
OHO Hartmann
O Hartmann

6 June 2003 in Cancer
Verified
Journal Article
Open access
PDF file
NGNathalie Gaspar
Nathalie Gaspar
OHOlivier Hartmann
Olivier Hartmann
CMCaroline Munzer
Caroline Munzer
CBChristophe Bergeron
Christophe Bergeron
FMFrédéric Millot
Frédéric Millot
CCCarole Coze
Carole Coze
BACKGROUND: Less than 5% of neuroblastomas are diagnosed in adolescent patients. Previous studies of patients who were treated with less intensive chemotherapy regimens relative to currently available regimens suggested that adolescents survived longer than younger children, and this finding was related to a lack of myc‐N amplification. Those reports prompted the authors to study a cohort of adolescent patients who had been included in more recent trials.METHODS: The authors investigated the presentation, treatment, and outcome in 28 adolescent patients who were enrolled in studies of the French Society of Pediatric Oncology during the period from 1987 to 1999 and who were older than age 10 years at the time they were diagnosed with neuroblastoma. The results were used to compare this subpopulation with a control group of children.RESULTS: None of the six patients with Stage I–II disease either developed recurrent disease or died. At 5 years, disease progression was high (progression‐free survival [PFS], 28%) for the 9 adolescents with Stage III disease, but so was survival (overall survival [OS], 86%). The 13 adolescent patients with metastatic neuroblastoma had very poor outcomes (PFS, 18%; OS, 27%). Despite intensive therapy, advanced neuroblastoma appeared to carry a poorer prognosis in adolescent patients compared with children, although patients with Stage III disease had a more indolent course. No difference was found between adolescent patients and children regarding the clinical presentation, treatment schedule, or doses and tolerance of chemotherapy. The incidence of elevated urinary catecholamine metabolite secretion was lower in adolescents compared with children.CONCLUSIONS: Adolescent patients with advanced neuroblastoma had less favorable outcomes compared with children, even if survival in adolescents with Stage III disease seemed longer. Cancer 2003;98:349–55. © 2003 American Cancer Society.DOI 10.1002/cncr.11521

1 April 1992
Verified
Journal Article
Closed access
CKC Kalifa
C Kalifa
OHO Hartmann
O Hartmann
FDF Demeocq
F Demeocq
GVG Vassal
G Vassal
DCD Couanet
D Couanet
JLJ Lemerle
J Lemerle

1 February 1998
Verified
Journal Article
Closed access
DSD Satgé
D Satgé
ASA J Sasco
A J Sasco
NCN L Carlsen
N L Carlsen
CSCharles Stiller
Charles Stiller
HRH Rubie
H Rubie
DSD Sommelet
D Sommelet

1 July 2002 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
DOD Oppenheim
D Oppenheim
DVD Valteau-Couanet
D Valteau-Couanet
SVS Vasselon
S Vasselon
OHO Hartmann
O Hartmann
Our objective was to understand the parents’ perception of children treated in an ASCT unit. Parents (40) of children and adolescents were interviewed by the department psychiatrist-psychoanalyst, over 9 months. They expressed great distress (22), considerable difficulty in assuming their parental role (with feelings of helplessness and guilt), and had distorted relations with the child whose behavior was unusual and incomprehensible (22). The relation with care providers, who should be ‘all-powerful’ and harmless, was ambivalent (15). They found it difficult to think or refused to do so, because their ‘thoughts are terrifying’, and they wanted to forget everything (11). The couple was going through a crisis (9). Temporal landmarks were disturbed (8); ASCT was experienced as a threatening discontinuity in the course of treatment (parents were unable to think of the past, the future, or the present); social landmarks were disturbed (6) with loss of social and professional relations. We concluded that parents may experience intense distress and disorientation. Trained to understand the parents’ and their children's thoughts and behavior, the medical team, which includes a psycho-oncologist, can better help them to understand and support the children, to strike a balance between their parental role and other responsibilities, and prevent conflicts.